Abstract

Keeping track of translational research is essential to evaluating the performance of programs on translational medicine. Despite several indicators in previous studies, a consensus measure is still needed to represent the translational features of biomedical research at the article level. In this study, we first trained semantic representations of biomedical entities and documents (i.e., bio-entity2vec and bio-doc2vec) based on over 30 million PubMed articles. With these vectors, we then developed a new measure called Translational Progression (TP) for tracking biomedical articles along the translational continuum. We validated the effectiveness of TP from two perspectives (Clinical trial phase identification and ACH classification), which showed excellent consistency between TP and other indicators. Meanwhile, TP has several advantages. First, it can track the degree of translation of biomedical research dynamically and in real-time. Second, it is straightforward to interpret and operationalize. Third, it doesn't require labor-intensive MeSH labeling and it is suitable for big scholarly data as well as papers that are not indexed in PubMed. In addition, we examined the translational progressions of biomedical research from three dimensions (including overall distribution, time, and research topic), which revealed three significant findings. The proposed measure in this study could be used by policymakers to monitor biomedical research with high translational potential in real-time and make better decisions. It can also be adopted and improved for other domains, such as physics or computer science, to assess the application value of scientific discoveries.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.